Skip to main content

Market Overview

Chardan Starts Coverage Of Mesoblast, Sees 'Large Market Opportunities'

Chardan Starts Coverage Of Mesoblast, Sees 'Large Market Opportunities'

Chardan Capital’s Keay Nakae has initiated coverage of Mesoblast limited (ADR) (NASDAQ: MESO) with a Neutral rating and price target of $5.50.

Nakae believes that there are several positives for the company, such as its proprietary mesenchymal lineage adult stem cells (MLCs), which can be formulated into allogeneic “off-the-shelf” cell products.

MLCs are capable of commercial scale, especially if Mesoblast considers a strategic partnership with Lonza, “a global leader in biopharmaceutical manufacturing.”

Related Link: Credit Suisse Bullish On Most Big Pharma Names

Mesoblast’s advanced clinical pipeline includes five cell therapy candidates that are either Phase 3-ready or in active Phase 3 trials.

“Most of these indications represent large market opportunities, so success in any one of them could generate significant economics for the company,” Nakae said.

On the other hand, the analyst also noted that regenerative medicine stocks have disappointed investors over the past few years. Mesoblast’s share price has also declined since 2010, with the U.S. IPO being poorly received.

“In part, we believe that this under-performance is a reflection of how the regenerative medicine space itself is evolving, which has seen a number of clinical trials producing mixed results,” Nakae added.

Image Credit: Public Domain

Latest Ratings for MESO

Apr 2021Maxim GroupUpgradesHoldBuy
Jan 2021JefferiesDowngradesBuyHold
Dec 2020Maxim GroupDowngradesBuyHold

View More Analyst Ratings for MESO
View the Latest Analyst Ratings


Related Articles (MESO)

View Comments and Join the Discussion!

Posted-In: Chardan Capital MarketsAnalyst Color Biotech Health Care Initiation Analyst Ratings Trading Ideas General

Latest Ratings

SAMEvercore ISI GroupMaintains1,500.0
SEAutonomous ResearchInitiates Coverage On378.0
ALHCMorgan StanleyInitiates Coverage On36.0
ALHCRaymond JamesInitiates Coverage On30.0
HAEMorgan StanleyDowngrades83.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at